Abstracts tagged "central nervous system involvement and systemic lupus erythematosus (SLE)"

Abstract Number: 1851 • 2015 ACR/ARHP Annual Meeting
Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus
Kazuhisa Nozawa¹, Kentaro Doe², Kaori Hiruma³, Yusuke Yamada⁴ and Yoshinari Takasaki⁵, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²2-1-1 Hongo, Bunkyo-Ku, Juntendo University School of Medicine, Tokyo, Japan, ³Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized in patients with SLE. PCNA constitutes PCNA-complex along with several PCNA-binding…
Abstract Number: 1169 • 2014 ACR/ARHP Annual Meeting
Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Maria B Lauvsnes¹, Mona K Beyer², Jan T Kvaløy^3,4, Ole J Greve⁵, Simone Appenzeller⁶, Erna Harboe⁷, Anne B Tjensvoll⁸, Lasse G Gøransson⁷ and Roald Omdal⁹, ¹Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ³Research Department, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway, ⁵Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, ⁷Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ⁹Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Antibodies against the NR2 subtype of the NMDA-receptor (anti-NR2 antibodies) are detected in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].